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Deferoxamine augments growth and pathogenicity of Rhizopus, white
hydroxypyridinone chelators have no effect. Deferoxamine (DFO), when
used in dialysis patients, is a well recognized risk factor for the
development of mucormycosis caused by Rhizopus. This study com-
pares, both in vivo and in vitro, the effects produced on Rhizopus by
DFO and by two chelators of the hydroxypyridinone class, LI and
CP94. Experimental systemic mucormycosis was induced in the guinea
pig by an i.v. injection of two different strains of Rhizopus: R.
microsporus and R. arrhizus, Concomitant i.p. administration of DFO
for four days shortened animal survival (P < 0.05), whereas concomi-
tant administration of either LI or CP94 did not. In vitro radioiron
uptake by R. microsporus was 100-fold higher from the '5ferric complex
of DFO than of Ll or CP94. In vitro fungal growth was stimulated
sevenfold by the ferric complex of DFO (P < 0.0001) but not signifi-
cantly by the ferric complex of either LI or CP94. These results indicate
that the ferric complex of DFO but not that of Li or CP94 specifically
stimulates both the iron uptake and the growth of Rhizopus. They
suggest that the risk of developing mucormycosis should be minimal
with Li or CP94, as opposed to DFO.
The most severe side effect of deferoxamine (DFO) therapy
in dialysis patients is the development of mucormycosis, caused
by Rhizopus. Recently, an international registry reported 46
dialysis patients who developed this DFO-associated fungal infec-
tion, which was fatal in 41 of 46 (89%) of the patients [1]. Apart
from clinical data, other evidence linking DFO and mucormycosis
has accumulated during the past few years. Experimentally in-
duced mucormycosis is aggravated by the administration of DFO
or its iron complex feroxamine (FO) [2—4]. Moreover, Rhizopus
has been shown to take up radioiron from radiolabeled FO and to
enhance its growth in the presence of FO [5].
New classes of iron or aluminum chelators, chemically unre-
lated to DFO, are in the process of intense investigation. Among
these, the class of the 3-hydroxypyridin-4-ones has gained the
greatest interest, the two most studied compounds being the 1,
2-dimethyl derivative (CP 20, better known as "Li" and recently
named deferiprone) and the 1 ,2-diethyl derivative (CP 94) [6, 7].
We compared the effects of these new chelators with those of
DFO upon Rhizopus in vitro as well as in vivo. This study shows
that, in contrast to DFO, neither Li nor CP94 stimulate Rhizopus'
growth in vitro or aggravate experimental mucormycosis.
Methods
Fun gal strains
Two clinical strains of Zygomycetes, order Mucorales, family
Mucoraceae, genus Rhizopus were studied. The first was
Rhizopus microsporus var. rhizopodiformis, referred here in as
R. microsporus (B5 1321, ATCC 66276), the second was Rhizo-
pus arrhizus (B5i322, ATCC 66275). Details on both strains
have previously been reported [8]. The strains were lyophiized
and maintained on Sabouraud dextrose agar (Difco, Detroit,
Michigan, USA). Sporangiospores (spores) were prepared by
growing the fungi on the same medium for 10 days. The
mycelium was scraped in sterile deionized water (Milli Q,
Millipore, Bedford, Massachusetts, USA); the sporulated my-
celia! suspension was vigorously agitated for 10 minutes in the
presence of glass beads (mean diameter of ca. 2 mm) and then
filtered through gauze. The eluate containing spores was
washed twice with water and concentrated by centrifugation to
obtain a suspension free of hyphal fragments which contained
about io spores/mi, as estimated with a BUrker hemocytome-
ter. Spores were stored at 4°C in the presence of penicillin and
streptomycin at 30 and 70 pg/mi, respectively [9].
Chelators
DFO was the commercially available Desferal' (Ciba Geigy,
Basel, Switzerland). FO or 55F0 were prepared as previously
described [10] by mixing stoichiometrically DFO with FeC13 or
55FeC13, respectively (Amersham Intern., Buckinghamshire,
UK). Li (1 ,2-dimethyi-3-hydroxypiridin-4-one) and CP94 (1,2-
diethyl-3-hydroxypyndin-4-one) were provided by Dr. M.
Stockham (British Technology Group, London, UK) and by Dr.
J. Yi (Ciba Geigy, Basel, Switzerland). Ferric complexes were
prepared by mixing Li and CP94, respectively, with 55FeC13,
with a stoichiometry of 3:1 (ligand:iron).
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In vivo experiments
Animals. Normal, non-predisposed male Albino guinea pigs
(Pirbright strain) weighing 500 50 g were infected i.v. with 293
colony forming units (CFU) of R. microsporus/g body wt and
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with 3,550 CFU of R. arrhizuslg body wt. Details on these
fungal inocula have previously been reported [2].
Experimental protocol. For each of the two fungal strains,
five experimental groups were studied, each consisting of six
animals. All 60 animals were infected. Those of group 1
remained untreated, while those of groups 2 to 5 received four
i.p. injections (1 ml) of either saline (group 2), DFO (group 3),
Li (group 4) or CP94 (group 5). Injections were given on four
consecutive days (day —1 to day +2, with reference to the
infection). All three chelators were dissolved in saline and
dosed at 50 mg/kg body wt. In three more experimental groups,
each of the three studied chelators was administered at the
same dosage to non-infected animals.
Assessment. Animals were observed daily; survival was
recorded up to day 28. At autopsy, cultures from eight organs
per animal (lung, liver, spleen, left kidney, brain, heart, left eye
and skin of the back) were performed on Sabouraud agar at
37°C.
In vitro experiments
Fun gal growth and fun gal iron uptake. Experiments were
carried out as recently reported [5]. The growth of R. mi-
crosporus was studied by a turbidimetnc determination at 400
nm [ii], performed after cultivation in BDM (basal defined
medium), a synthetic medium designed for mammalian cell
cultivation, having an iron content of 1.36 tM [12]. 106 spores
were incubated in 2.1 ml of medium containing 40% human
serum, in the presence or absence of ferric complexes of the
three chelators at 1 /SM. After 24 hours at 37°C, fungal elements
were centrifuged and washed. Pellets were harvested and
analyzed.
Iron transfer. 55Fe-radioiabeled Fe(Li)3 or FO at 30 /.M were
added to serum from healthy volunteers and separated by
agarose gel electrophoresis (Ciba Corning, Palo Alto, Califor-
nia, USA), run in 0.05 M veronal buffer, pH 8.6. The serum had
following characteristics: iron content 16.7 M; transferrin 2.40
mg/mI, (30 MM); and iron saturation of transferrin 24%. After
electrophoresis, the gel was dried; autoradiography was carried
out with HyperfilmTM-/3 max (Amersham mt., Buckingham-
shire, UK).
Statistical analysis
Mean values are given together with SEM. Statistical signifi-
cance between study groups was determined by the two-tailed
probability Mann-Whitney U test (comparison of survival) or
by the one-factor ANOVA test.
Results
In vivo
Table 1 compares the effects of Li and CP94 versus DFO
upon the course of experimental mucormycosis caused by R.
microsporus and R. arrhizus, respectively. The results obtained
with these two strains are similar. DFO (group 3) significantly
shortened mean survival, from 5.0 0.5 to 3.2 0.2 days and
from 7.8 1.1 to 4.8 0.3 days, respectively (P < 0.05). In
contrast, neither Li nor CP94 (groups 4 and 5) exerted a
significant effect when compared to saline. The effect of DFO
upon survival of the infected animals was significantly different
from that of either Li or CP94. The animals died from dissem-
Table 1. Effect of different chelators on the outcome of experimental
mucormycosis
Survival
Treatment (days, mean SEM) P°
R. microsporus
none 4.0 0.2
saline
DFOb
LV'
CP941'
5.0 0.5
3.2±0.2
4.0 0.2
4.7 0.3
1
.3 -1
.3
J
R, arrhizus
none 9.5 0.7
saline
DFOb
LI1'
CP941'
7.8 1.1
4.8 0.3
16.2 4.0
8.7 1.0
J
.3
J
P 0.05; **a Mann-Whitney U test (two-tailed probability). *
0.01
b 50 mg kg of deferoxamine (DFO), the I ,2-dimethyl- and the
1,2-diethyl derivative of 3-hydroxypyridin-4-one ("Li" and "CP94",
respectively), administered i.p. in I ml saline for four consecutive days
(days —1 to +2 of infection)
mated mucormycosis, as indicated by positive fungal cultures
obtained in 91 to 100% of the organs cultured within each
experimental group.
Non-infected animals, given either DFO, Li or CP94 at 50
mg/kg for four consecutive days, all remained alive until the end
of the study period (28 days).
In vitro
Figure 1A shows that 1 M FO significantly stimulated the
fungal growth of R. microsporus in BDM containing 40%
human serum (7.3-fold increase, P < 0.0001). In contrast,
equimolar ferric complexes of Li or CP94 did not significantly
modify the fungal growth rate. Phase contrast microscopy
confirmed the effect of the three ferri-chelators on Rhizopus
growth. When added to 40% human serum, which inhibits
fungal growth, FO strongly stimulated the growth of Rhizopus,
whereas Fe(Li)3 or Fe(CP94)3 only minimally affected its
growth (not shown).
Fungal radioiron uptake from the "Fe complex of the three
chelators was compared in Figure lB. R. microsporus accumu-
lated about 100-fold more radioiron when bound to DFO (1,131
63 pmolJiO6 fungal particles) than when bound to Li or CP94
(13 1 and ii 3 pmol/l06 fungal particles, respectively). The
in vitro effects of DFO, both upon fungal growth and upon
fungal iron accumulation, were significantly different from the
effects observed for Li and CP94.
Autoradiography of an agarose gel showed that, in the
presence of human serum, nearly 50% of the radioiron was
released from Fe(Li)3, but not from FO to apotransferrin (Fig.
2).
Discussion
The present results confirm that DFO significantly aggravates
mucormycosis, induced in non-predisposed guinea pigs by the
i.v. injection of spores from two different species of Rhizopus.
The degree of shortening of animal survival induced by DFO is
similar to that previously reported, indicating consistency in the
model of experimental infection used as well as in the drug's
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Fig. 1. Growth (A), measured by turbidimetry, and radioiron uptake
(B) of Rhizopus, cultured for 24 hours in BDM with 40% human serum
alone (control) or supplemented with the iron complex of deferoxamine
and the iron complex of the 1,2-dimethyl- and of the 1,2-diethyl
derivative of3-hydroxypyridin-4-one ("LI" and "CP94"), respectively.
Symbols are: (in A) (0) BDM + 40% serum (control); (Efl) + FO; (0)
+ Fe(Ll)3; (J) + Fe(CP94)3; and in (B) ( ) 55F0; (0) 55Fe(Ll)3; (0)
55Fe(CP94)3.
effect [21. Abe et al reported similar results in mice; all mice
pretreated with DFO or FO died within five days after i.v.
inoculation of R. arrhizus, whereas the mortality in the infected
but untreated animals was only 20% through the three-week
experimental period [31. More recently, DFO was successfully
used to produce rhinocerebral mucormycosis in mice which
were challenged intraethmoidally with R. arrhizus [4].
During the last few years, the mechanism of this effect of
DFO on Rhizopus has been investigated. When challenged to
iron limitation, Rhizopus does not synthesize DFO but an
unrelated siderophore, called rhizoferrin, consisting of two
citric acid and one diaminobutane residues [13]. Nevertheless,
Rhizopus can mobilize iron presented by the exogenous hy-
droxamate siderophore FO. Figure lB confirms the intense
fungal accumulation of 55Fe from 1 tM 55F0. Even at a 55F0
concentration as low as 0.01 LM, 55Fe uptake occurred, leading
to disruption of serum fungistasis and to stimulation of the in
vitro growth of Rhizopus in a serum-containing medium [5, 14].
Figure 1A shows the significant enhancement of the in vitro
growth of Rhizopus induced by the addition of 1 M P0. This
siderophore-mediated iron uptake and growth stimulation is
considered to play a key role in the aggravation of experimental
mucormycosis by DFO as well as in the pathogenesis of
DFO-mediated human mucormycosis [5].
How specific is this interaction between Rhizopus and FO? In
a previous study, we compared the effect of FO upon three
different fungal genera and found that FO had a greater effect on
Rhizopus than on the two other studied species, that is,
radioiron uptake from 55F0 by R. microsporus was eightfold
and 40-fold greater than that by Aspergillus fumigatus and by
Candida albicans, respectively [5].
In the present study, the question on the specificity of the
interaction between Rhizopus and FO was addressed at the
chelator level: how specific to FO is the siderophore effect on
Rhizopus? For comparison, two compounds of the 3-hydroxy-
pyridin-4-one class were chosen for several reasons. First, this
class of chelators is chemically unrelated to hydroxamate
siderophores, such as DFO. Second, Ll has been investigated
as a chelator of iron both in cell culture and in animal studies,
and it has been administered orally to several hundreds of
patients with iron overload with encouraging results [7, 15, 16].
Third, some preliminary evidence in rats indicates that Li is
also an effective chelator of aluminum, as Li was comparable to
DFO in its effect on aluminum removal from the bone in uremic
rats with aluminum intoxication [17]. Furthermore, a pilot study
suggests that the aluminum complex of Li and its glucoronide
conjugate are readily removed by both hemo- and peritoneal
dialysis in patients [18]. CP94, being possibly a more efficacious
iron chelator than Ll [19], was also included in the present
study.
In vitro radioiron uptake by Rhizopus from the 55ferric
complex of Li or CP94 is 100-fold lower than from equimolar
55F0 (Fig. iB). Correspondingly, iron-bound Li or CP94 at 1
LM does not significantly influence the in vitro growth rate of
Rhizopus in a serum-containing culture medium. This is in
sharp contrast with equimolar FO, which increases fungal
growth 7.3-fold (Fig. iA). The low rate of fungal iron uptake
from ferric Li or CP94 could possibly be explained by the
release of iron from these chelators to apotransferrin, as ob-
served by autoradiography (Fig. 2) and as reported by others
[20].
This different in vitro handling by Rhizopus of hydroxypyri-
dinones compared to DFO results in different chelator effects
on experimental mucormycosis. Neither Li nor CP94 influ-
enced the course of this infection, whether induced by R.
microsporus or by R. arrhizus. The effect of both chelators is
therefore significantly different from the observed DFO effect.
The lack of effect of L 1 or CP94 cannot be attributed to
underdosing, as the dosage used yielded a 1.5- and 1.3-fold
higher molar concentration, respectively, than for DFO when
compared on an iron-binding equivalence base (1:1 for the
DFO-iron complex and 3:1 ligand-iron complex for Li and
CP94). Although the hydroxypyridinone chelators are primarily
designed for oral use [6, 15, 16], it is highly unlikely that the
absence of effect on mycormycosis should be due to the i.p.
route used, as the effectiveness (degree of iron mobilization) of
Li and CP94 by the i.p. and by the oral route are reported to be
identical [21].
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Fig. 2. Autoradiography of agarose gel with 55Fe-radiolabeled human transferrin alone [1), FO alone [2], Fe(L1)3 alone [3] and with either 30 pM
FO with human serum [4] or 30 psi Fe(LI)3 with human serum [5]. Specific migration bands are shown: A for FO, B for transferrin, C for Fe(L1)3.
The starting line is indicated by an arrow.
The present study was not designed to assess the potential
usefulness of Li or CP94 in replacement of DFO in the
management of the aluminum- or iron overloaded dialysis
patient. The effectiveness of Li, given cumulatively to more
than 450 non-uremic patients with iron overload, is well docu-
mented. The main concern is the occurrence of transient
agranulocytosis in 5 of the 450 patients [221.The long-term use
of Li as chelator of aluminum in uremic patients has not been
reported yet. However, if the drug proves to be effective and
safe in this patient population, our study indicates that Rhizo-
pus handles Li and CP94 differently from DFO and it suggests
that the risk of developing mucormycosis should be minimal
with Li or CP94, in contrast with DFO. It also shows that in
vitro studies on the relationship between chelators and Rhizo-
pus can help predict in vivo consequences. The same has been
found for other microorganisms [23]. As DFO remains at
present the standard drug in clinical chelation therapy, guide-
lines restricting the use of DFO and lowering its dosage in
dialysis patients should be applied in the hope of lessening the
risk of mucormycosis [24]. However, it remains to be proved
that using the lower DFO dosage proposed at a recent consen-
sus conference [24] will be effective in reducing the risk of
mucormycosis.
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